Pharmacotherapy of motor symptoms in early and mid-stage Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology
Matthias Höllerhage,Jos Becktepe,Joseph Classen,Günther Deuschl,Georg Ebersbach,Franziska Hopfner,Paul Lingor,Matthias Löhle,Sylvia Maaß,Monika Pötter-Nerger,Per Odin,Dirk Woitalla,German Parkinson’s Guidelines Group,Claudia Trenkwalder,Günter U Höglinger,Mathias Bähr,Daniela Berg,Kathrin Brockmann,Carsten Buhmann,Andrés Ceballos-Baumann,Joseph Claßen,Cornelius Deuschl,Richard Dodel,Carsten Eggers,Thilo van Eimeren,Alessandra Fanciulli,Bruno Fimm,Ann-Kristin Folkerts,Madeleine Gausepohl,Alkomiet Hasan,Wiebke Hermann,Rüdiger Hilker-Roggendorf,Günter Höglinger,Wolfgang Jost,Elke Kalbe,Jan Kassubek,Stephan Klebe,Christine Klein,Martin Klietz,Thomas Köglsperger,Andrea Kühn,Paul Krack,Florian Krismer,Gregor Kuhlenbäumer,Johannes Levin,Inga Liepelt-Scarfone,Kai Loewenbrück,Stefan Lorenzl,Walter Maetzler,Regina Menzel,Philipp T Meyer,Brit Mollenhauer,Manuela Neumann,Tiago Outeiro,René Reese,Kathrin Reetz,Olaf Rieß,Viktoria Ruf,Anja Schneider,Christoph Schrader,Alfons Schnitzler,Klaus Seppi,Friederike Sixel-Döring,Alexander Storch,Lars Tönges,Uwe Walter,Tobias Wächter,Tobias Warnecke,Florian Wegner,Christian Winkler,Karsten Witt,Kirsten Zeuner
DOI: https://doi.org/10.1007/s00415-024-12632-6
2024-08-29
Abstract:Background and objective: There are multiple pharmacological treatment options for motor symptoms of Parkinson's disease (PD). These comprise multiple drug classes which are approved for the condition, including levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors, NMDA-receptor antagonists, anticholinergics, and others. Some of the drugs are approved for monotherapy and combination therapy while others are only approved as adjunctive therapy to levodopa. Furthermore, treatment for special treatment situations, e.g., rescue medication for off-phases, for tremor, treatment during pregnancy and breast feeding is discussed and recommendations are given with further details. Methods: The recommendations were based on systematic literature reviews, drafted by expert teams, consented in online polls followed by online consensus meetings of the whole German Parkinson's Guideline Group, and publicly released in November 2023. Results: In the new S2k (i.e., consensus-based) guidelines, the pharmacotherapy of the motor symptoms of PD is discussed in five chapters. These comprise "Parkinson medication", "Initial monotherapy", "Early combination therapy", "Fluctuations and dyskinesia", and "Parkinsonian tremor". Furthermore, there is a chapter for special treatment situations, including perioperative management, freezing of gait, and pregnancy and breastfeeding. Conclusion: The recommendations for the pharmacotherapy of motor symptoms of PD have been updated. Newly available drugs have been added, while other drugs (e.g., ergoline dopamine agonists, anticholinergics, budipine) have been removed from the recommendations.